Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis
Authors:
- Srinivasa P S RaoSRSrinivasa P S Rao
- Suresh B LakshminarayanaSLSuresh B Lakshminarayana
- Jan JiricekJJJan Jiricek
- Marcel KaiserMKMarcel Kaiser
- Ryan RitchieRRRyan Ritchie
- Elmarie MyburghEMElmarie Myburgh
- Frantisek SupekFSFrantisek Supek
- Tove TuntlandTTTove Tuntland
- Advait NagleANAdvait Nagle
- Valentina MolteniVMValentina Molteni
- Pascal MäserPMPascal Mäser
- Jeremy C MottramJMJeremy C Mottram
Open Access
- 17 February 2020
- journal article
- research article
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 5 (1) , 28
Abstract
Current anti-trypanosomal therapies suffer from problems of longer treatment duration, toxicity and inadequate efficacy, hence there is a need for safer, more efficacious and ‘easy to use’ oral drugs. Previously, we reported the discovery of the triazolopyrimidine (TP) class as selective kinetoplastid proteasome inhibitors with in vivo efficacy in mouse models of leishmaniasis, Chagas Disease and African trypanosomiasis (HAT). For the treatment of HAT, development compounds need to have excellent penetration to the brain to cure the meningoencephalic stage of the disease. Here we describe detailed biological and pharmacological characterization of triazolopyrimidine compounds in HAT specific assays. The TP class of compounds showed single digit nanomolar potency against Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense strains. These compounds are trypanocidal with concentration-time dependent kill and achieved relapse-free cure in vitro. Two compounds, GNF6702 and a new analog NITD689, showed favorable in vivo pharmacokinetics and significant brain penetration, which enabled oral dosing. They also achieved complete cure in both hemolymphatic (blood) and meningoencephalic (brain) infection of human African trypanosomiasis mouse models. Mode of action studies on this series confirmed the 20S proteasome as the target in T. brucei. These proteasome inhibitors have the potential for further development into promising new treatment for human African trypanosomiasis.Keywords
Funding Information
- Wellcome Trust (WT-103024MA, WT-104976)
This publication has 21 references indexed in Scilit:
- The skin is a significant but overlooked anatomical reservoir for vector-borne African trypanosomeseLife, 2016
- Trypanosoma brucei Parasites Occupy and Functionally Adapt to the Adipose Tissue in MiceCell Host & Microbe, 2016
- Comparative genomics of drug resistance in Trypanosoma brucei rhodesienseCellular and Molecular Life Sciences, 2016
- Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors ofTrypanosoma bruceiJournal of Medicinal Chemistry, 2015
- Identification and Characterization of Hundreds of Potent and Selective Inhibitors of Trypanosoma brucei Growth from a Kinase-Targeted Library Screening CampaignPLOS Neglected Tropical Diseases, 2014
- Epidemiology of human African trypanosomiasisClinical Epidemiology, 2014
- SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African TrypanosomiasisPLOS Neglected Tropical Diseases, 2011
- N-myristoyltransferase inhibitors as new leads to treat sleeping sicknessNature, 2010
- Artificial Membrane Assays to Assess PermeabilityCurrent Drug Metabolism, 2008
- Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein BindingJournal of Pharmaceutical Sciences, 2008